GEN Exclusives

More »

GEN News Highlights

More »
Aug 12, 2009

S-Evans Biosciences Gains Chinese Rights to Cryo-Cell’s Menstrual Stem Cell Technology

  • Cryo-Cell granted Chinese company S-Evans Biosciences (SEB) an exclusive license to market and manufacture its C'elle menstrual stem cell technology including processing and storage of menstrual stem cells throughout mainland China. The deal also allows SEB to conduct research using this platform to identify potential therapeutic applications for a range of diseases.

    The C'elle service is based on Cryo-Cell's patent-pending IP portfolio and was introduced in November 2007 as a service that allows women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future potential utilization by the donor or possibly first-degree relatives in a manner similar to umbilical cord blood stem cells.

    The agreement provides Cryo-Cell future royalty fees from the processing and annual storage of menstrual stem cells.

    SEB is located near Shanghai in Hangzhou, Zhejiang Province, People's Republic of China. It reportedly collaborates with several local institutions, hospitals, and Zhejiang-California International Nanosystems Institute (ZCNI). ZCNI is a Sino-U.S. institute for biomedicine and nanotechnology research located on Zhejiang University campus.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?